Alterity Therapeutics Limited (ATHE) Stock Score, Valuation & Financial Research

Alterity Therapeutics Limited is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ATHE

Alterity Therapeutics Limited does not currently have a complete Wall Street Score. The stored market price is USD 3.37. These figures are a research snapshot, not a buy or sell recommendation.

What Alterity Therapeutics Limited does

Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.

Company business and revenue

Research reporting period: 2026-06-30. A research update is not a new financial filing.

How the company makes money

Alterity Therapeutics is a clinical-stage biotechnology company that does not currently generate commercial revenue. Its business model relies on research and development of proprietary drug candidates, specifically targeting neurodegenerative diseases like Multiple System Atrophy, funded through capital raises and government R&D tax incentives.

Products and services

  • The company is developing ATH434, a small molecule drug candidate for the treatment of Multiple System Atrophy (MSA) and other Parkinsonian disorders, alongside a drug discovery platform for neurological disease compounds.

Brands and product families

  • ATH434 — Lead drug candidate for the treatment of Multiple System Atrophy. Source

Customer types

Healthcare providers and patients with neurodegenerative disorders.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company engages various unnamed third-party contract research organizations to conduct clinical trials and provide specialized laboratory services. Source

Competitors and product-market comparisons

  • Biopharmaceutical companies — The company competes with various global biopharmaceutical firms developing treatments for Parkinsonian disorders and neurodegenerative diseases. Source

Business strengths to evaluate

  • Proprietary drug discovery platform Source
  • Clinical progress of lead candidate ATH434 Source

Business risks and research considerations

  • History of operating losses and dependence on future capital raises Source
  • Clinical trial failure and regulatory approval uncertainty Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ATHE financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.37
Market capitalization:
57.09M (currency not supplied)
Revenue:
USD 3.78M
Net income:
USD -24.74M
Free cash flow:
USD 0.00
Cash:
USD 25.96M
Total debt:
USD 134.59K
EPS:
USD -1.79

What stands out

  • Free cash flow is USD 0.00, zero for the stored period.
  • The balance sheet shows USD 25.96M of cash versus USD 134.59K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is 0.0% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -653.9% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 25.83M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ATHE

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Why is ATHE's stored free cash flow zero, and do the filing and calculation confirm that value?
  • How is ATHE likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ATHE to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of ATHE's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ATHE

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.